VAL-083 Creates DNA N7 Methylation with Antitumor Activity

Glioblastoma (GBM) is one of the most difficult tumors. Many new agents fail to cross the blood-brain barrier (BBB) and it has intrinsic drug resistance.

VAL-083 is an alkylating agent that creates N7 methylation on DNA. Additionally, VAL-083 suppresses U251 and SF188 cell growth and induces apoptosis after 72 h. This compound at 5 μM inhibits the growth of SF188 by 95%. At the same time, VAL-083 inhibits T98G cells’ growth in a dose-dependent manner (IC50 <5 μM). However, VAL-083 inhibits the proliferation of HUVEC and U251 cells at doses of more than 12.5 μg/mL. VAL-083 (3.125, 6.25, 12.5 μg/mL) also suppresses the migration and invasion. And it reduces MMP2, VEGF, VEGFR2, and FGF2 expression in HUVEC and U251 cells.

VAL 083 Creates DNA N7 Methylation with Antitumor Activity 2022 02 19 03 scaled - VAL-083 Creates DNA N7 Methylation with Antitumor Activity

In the glioma cell lines, VAL-083 (1, 2, 5 μM) dose-dependently induces cell cycle arrest at the G2/M phase. Furthermore, VAL-083 activates two parallel signaling cascades, the p53-p21, and the CDC25C-CDK1 cascade. In addition, VAL-083 significantly enhances the radiosensitivity of LN229 cells.

In a zebrafish model, VAL-083 dose-dependently inhibits angiogenesis. It considerably reduces VEGF, VEGFR2, and FGF2 expression at 25 μg/mL. And it furtherly causes a reduction in FGFR2 expression at 50 μg/mL.

In a tumor mice model, after VAL-083 intravenous injection at dosage 5 mg/kg; After 6 weeks, It significantly blocks the growth of LN229 cells in mice with the relative tumor growth rate (T/C) of 22.38%. Besides, it exhibits a tumor growth inhibitory rate (TGI) of 83.58%. Moreover, VAL-083 dramatically activates the CDC25C-CDK1 cascade in the xenografted tumor model.

In conclusion, VAL-083 is a potent alkylating agent. And this compound exhibits anti-tumor activity in vitro and in vivo. It has the potential for cancer research.


[1]. Kaiji Hu, et al. Cancer Research. 2012 Mar 31-Apr 4.

[2]. Jiang X, et al.Biomed Pharmacother. 2017 Jul;91:1065-1074.